Bahrain

New York Community Bancorp, Inc. (NYSE: NYCB) (“NYCB” or the “Company”) announced today that it has completed previously announced transactions, resulting in individual investments totaling approximately $1. 05 billion in the Company through Liberty Strategic Capital (“Liberty”), controlled budget through Hudson Bay Capital Management (“Hudson’s Bay”), controlled budget through Reverence Capital Partners (“Reverence Capital”) and other investors (collectively, the “Investors”).

Plant-based cheese market sales are estimated at US$1,530. 2 million in 2022. Depending on the long-term market. . .

They’ve unveiled their designs, Drive to Survive has arrived on Netflix, and Red Bull looks strong, all of which indicate one thing: Formula 1 opens its 2024 season this weekend with the Bahrain Grand Prix.

A trio of Lockheed Martin F-16 Block 70 fighters departed Greenville, South Carolina, for Bahrain.

FORM 8. 3 PUBLIC DISCLOSURE OF TRADE OPENING POSITION/DISCLOSURE BY A PERSON WHO HAS INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MOREThe Code Rule 8. 3 (the “Code”) 1. (a) Full Discloser Call: Dimensional Fund Advisors Ltd. in in its capacity as an investment advisor and on behalf of its affiliates who are also investment advisors (“Dimensional”). Dimensional expressly relinquishes ownership of the shares described in this form. 8. 3. (b) Owner or Controller of Interests

Tinlarebant is an orally administered tablet of Belite Bio intended to slow disease progression in patients with Stargardt’s disease (STGD1) and geographic atrophy (GA) in complex dry age-related macular degeneration (dry AMD). Data from a 24-month phase 2 trial in adolescents. Subjects with STGD1 showed a decrease and durable expansion of atrophic lesion in subjects treated with Tinlarebant compared to ProgStar participants with baseline characteristics (age ≤ 18 years) (p <0. 001). In the Phase 2 trial,

PepsiCo, Inc. (NASDAQ: PEP) today announced that it will release its monetary effects for the first quarter of 2024 (ended March 23) and other similar data on Tuesday, April 23, 2024 by posting the following documents and links on the company’s website. in www. pepsico. com/investors.

FORM 8. 3 PUBLIC DISCLOSURE OF TRADE OPENING POSITION/DISCLOSURE BY A PERSON WHO HAS INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MOREThe Code Rule 8. 3 (the “Code”) 1. (a) Full Discloser Call: Dimensional Fund Advisors Ltd. in in its capacity as an investment advisor and on behalf of its affiliates who are also investment advisors (“Dimensional”). Dimensional expressly relinquishes ownership of the shares described in this form. 8. 3. (b) Owner or Controller of Interests

Donald Trump will have to be sick of winning, as he has just added a six-figure legal bill to his growing pile of. . .

CARLSBAD, Calif. , March 12, 2024 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a biotech company seeking remedies for serious degenerative genetic diseases, announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024 at 4:30 p. m. ET to discuss the monetary effects of the fourth quarter and full year 2023 and provide a full portfolio update. The event will be streamed live on the Internet in the “Events” segment of the Investors page.